TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05073458

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.
“A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”

The sponsor’s own words in the registry.

Life of this trial

202120222023202420252026Registered2021-09-28Started2022-03-15Primary completion2023-10-17Stopped2024-04-29Results posted2025-01-15

Vital statistics

Status
Terminated
Phase
Phase 3
Sponsor
Incyte Corporation
Sponsor type
Industry
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions
parsaclisinib; placebo
Participants
13
Sites
56
Countries
Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Spain, United Kingdom and more

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.